(Q35800704)

10 August 2017

Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study (English)

1 reference

10 August 2017

1 reference

1 reference

3

Kathryn A Carson

1 reference

10 August 2017

John J Laterra

1

1 reference

10 August 2017

Stuart A Grossman

2

1 reference

10 August 2017

Glenn J Lesser

4

1 reference

10 August 2017

Fred H Hochberg

5

1 reference

10 August 2017

Mark R Gilbert

6

1 reference

10 August 2017

NABTT CNS Consortium study

7

1 reference

10 August 2017

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

6

1 reference

10 August 2017

1

1 reference

10 August 2017

15-20

1 reference

Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineli

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Suramin modulates cellular levels of hepatocyte growth factor receptor by inducing shedding of a soluble form.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Suramin inhibits C6 glioma-induced angiogenesis in vitro.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Suramin binds to platelet-derived growth factor and inhibits its biological activity

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin. Implications for the mechanism of autocrine transformation

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Differential effects of suramin on the coupling of receptors to individual species of pertussis-toxin-sensitive guanine-nucleotide-binding proteins

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

The efficacy and distribution of suramin in the treatment of the 9L gliosarcoma

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Suramin inhibits glioma cell proliferation in vitro and in the brain.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871972

Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A

25 September 2018

1 reference

12 December 2020

Suramin is a Potent Inhibitor of Vascular Endothelial Growth Factor. A Contribution to the Molecular Basis of its Antiangiogenic Action

1 reference

12 December 2020

Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin

1 reference

12 December 2020

Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells

1 reference

12 December 2020

The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Organization, Objectives, and Activities

1 reference

12 December 2020

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

12 December 2020

Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma

1 reference

12 December 2020

Proliferation-Independent Growth Factor Modulation of the Radiation Sensitivity of Human Prostate Cells

1 reference

12 December 2020

Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma

1 reference

12 December 2020

10.1215/S1152851703000127

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

14769135

1 reference